Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
97 studies found for:    "Neurofibromatosis"
Show Display Options
Rank Status Study
21 Completed
Has Results
Pirfenidone in Children and Young Adults With Neurofibromatosis Type I and Progressive Plexiform Neurofibromas
Conditions: Neurofibromatosis 1;   Neurofibroma, Plexiform
Intervention: Drug: Pirfenidone
22 Active, not recruiting Sirolimus to Treat Plexiform Neurofibromas in Patients With Neurofibromatosis Type I
Conditions: Neurofibromatosis Type 1;   Plexiform Neurofibromas;   Paraspinal Plexiform Neurofibromas
Intervention: Drug: Sirolimus
23 Unknown  How Neurofibromatosis Type 1 (NF1) Affects Schoolwork and Self-Esteem
Condition: Neurofibromatosis Type 1
Intervention:
24 Unknown  Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
Condition: Neurofibromatosis Type II
Intervention: Drug: Everolimus (RAD001) , Afinitor®
25 Recruiting Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
Conditions: Neurofibromatosis Type 2;   Vestibular Schwannomas
Intervention: Drug: Axitinib
26 Active, not recruiting Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
Conditions: Vestibular Schwannoma;   Neurofibromatosis Type 2
Intervention: Drug: Endostatin
27 Active, not recruiting Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
Condition: Neurofibromatosis 2
Intervention: Drug: RAD001
28 Completed Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
Conditions: Neurofibromatosis Type I;   Plexiform Neurofibroma
Interventions: Drug: Nexavar (BAY 43-9006) (Sorafenib);   Drug: Toxicity, Pharmacokinetics;   Drug: Pharmacodynamics;   Drug: Radiographic Evaluation;   Drug: QOL assessment, Neuropsychological;   Drug: Bony Toxicity
29 Completed Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1)
Conditions: Tuberous Sclerosis;   Neurofibromatoses;   Angiofibroma;   Neurofibroma
Interventions: Drug: Skincerity;   Drug: Skincerity plus sirolimus/rapamycin;   Drug: Skinercity plus sirolimus/rapamycin
30 Recruiting Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis
Conditions: Whole Body Imaging;   Magnetic Resonance Imaging;   Neurofibromatosis 1;   Diffusion Magnetic Resonance Imaging;   Peripheral Nerve Sheath Tumors, Malignant
Intervention: Other: Additional imaging or surgery
31 Recruiting Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1
Condition: Neurofibromatosis Type 1
Intervention: Other: Neuropsychological examination and quality of life measures
32 Completed Clinical Trial of Pirfenidone in Adult Patients With Neurofibromatosis 1
Condition: Neurofibromatosis
Intervention: Drug: Pirfenidone
33 Completed Pirfenidone in Treating Young Patients With Neurofibromatosis Type 1 and Plexiform Neurofibromas
Conditions: Neurofibromatosis Type 1;   Precancerous Condition
Intervention: Drug: pirfenidone
34 Active, not recruiting Neurobiology and Treatment of Reading Disability in NF-1
Conditions: Neurofibromatosis Type 1;   Reading Disabilities
Interventions: Behavioral: Tutoring Program I;   Behavioral: Tutoring Program II
35 Active, not recruiting Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1
Conditions: Neurofibromatosis Type 1;   Cutaneous Neurofibromas
Intervention: Drug: Ranibizumab
36 Active, not recruiting A Randomized Placebo-Controlled Study of Lovastatin in Children With Neurofibromatosis Type 1
Condition: Neurofibromatosis Type 1
Interventions: Drug: Lovastatin ™;   Device: placebo
37 Recruiting Effect of Lamotrigine on Cognition in NF1
Condition: Neurofibromatosis Type 1
Interventions: Drug: Lamotrigine;   Drug: Placebo
38 Completed NF1-Attention: Study of Children With Neurofibromatosis Type 1 Treated by Methylphenidate
Condition: Neurofibromatosis Type 1
Intervention: Drug: methylphenidate
39 Active, not recruiting A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas
Condition: Neurofibromatosis Type 1
Intervention: Drug: Sirolimus, Rapamycin
40 Recruiting Genetic Evaluation of NF1 and Scoliosis Patients
Conditions: Neurofibromatosis 1;   Scoliosis
Intervention: Genetic: Swab

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years